Hussman Strategic Advisors Inc. Takes $658,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hussman Strategic Advisors Inc. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,200 shares of the company’s stock, valued at approximately $658,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp increased its stake in shares of Krystal Biotech by 9.0% in the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after acquiring an additional 11,411 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Krystal Biotech by 34.2% during the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after acquiring an additional 19,777 shares in the last quarter. Finally, Braidwell LP boosted its holdings in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after acquiring an additional 61,512 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Chardan Capital raised their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Finally, Citigroup lifted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $210.00.

Krystal Biotech Trading Up 3.7 %

KRYS stock opened at $182.62 on Friday. The stock has a 50-day moving average price of $157.18 and a 200-day moving average price of $175.18. Krystal Biotech, Inc. has a 1-year low of $107.50 and a 1-year high of $219.34. The firm has a market cap of $5.25 billion, a PE ratio of 103.18 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the company posted $0.30 EPS. The firm’s revenue was up 116.4% compared to the same quarter last year. On average, analysts forecast that Krystal Biotech, Inc. will post 3.22 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).